Vaxeal’s unique scientific strategy is based on T-cell-based cancer immunotherapies, combined to metronomic low doses Immune Checkpoint Inhibitors (ICIs). These combinations are overcoming both efficacy issues, by targeting specific cancer biomarkers (Survivin, Cyclin B1) and by overcoming tumor-mediated immunosuppressive mechanisms, and safety issues, by limiting immune-related adverse events induced by ICIs (CTLA-4 and PD-1/PD-L1 antibodies).
This innovative scientific strategy, which is at the forefront of oncology therapies, will ensure high clinical efficacy of Vaxeal’s immunotherapies, while limiting dramatically treatment side effects.
A personalized approach is also a key component of Vaxeal strategy and will dramatically improve efficacy of treatments. Vaxeal has, indeed, developed novel assays, called companion diagnostics, allowing it to select patients populations based on: 1) the presence of the selected biomarkers in the tumour, and 2) the absence of spontaneous immune tolerance of the patients.
Vaxeal has also designed its immunotherapies allowing to treat all patients independently to their HLA type(No HLA restriction).
All features considered for the design of Vaxeal’s vaccines represents a real medical breakthrough in the field of cancer.
